Paris, March 11, 2010 - Hybrigenics, a bio-pharmaceutical company with a focus on research and development of new cancer treatments and specialized in protein interactions, announced today that it has filed a new patent application protecting a crucial step in the synthesis of inecalcitol.
11 March 2010: Malvern, UK: Dr Hanna Jankevics, product technical specialist at Malvern Instruments is presenting the latest in light scattering methodologies for protein and peptide characterisation at The Peptide Conference 2010. The conference takes place at The Wellcome Trust Conference Centre in Cambridge, UK on 30 & 31 March. Dr Jankevics’ talk, ‘Light scattering for protein and peptide characterisation‘, is part of Tuesday morning’s Labelling and Characterisation, Session 2. Further program details can be found at: http://www.avakado.eu/dev/Biofine/Peptide/Conference/2010.
Grand Rapids, Mich. (March 11, 2010) – Van Andel Research Institute (VARI) researchers have developed a new method to better study the cells that line and protect the prostate in relation to the development of cancer. Using the model, they found that normal cells and cancer cells depend on different factors to survive, which could aid in discovering how to target cancer cells without affecting normal cells when developing treatments.
MONTREAL, March 11 /CNW/ - ConjuChem Biotechnologies Inc. announced that the Committee of independent Board members mandated to explore and evaluate all strategic alternatives have elected to engage Bloom Burton & Co., a leading Canadian healthcare investment banking firm, to further solicit and evaluate strategic options for the company with a view to maximize value for shareholders and other stakeholders.
LONDON, March 11, 2010-As part of an extension to its product development capabilities, Melbourn Scientific has become the first contract research organisation in Europe to invest in the award winning Morphologi G3, an automated image analysis system for particle characterisation and foreign particulate contamination.
MISSISSAUGA, Canada – March 11, 2010 – YM BioSciences Inc. (NYSE Amex: YMI, TSX: YM), today announced that that Mr. David Allan, Chairman and CEO, will be presenting at the 22nd Annual ROTH Orange County Growth Stock Conference.
TORONTO, March 11 - Spectral Diagnostics Inc. (TSX:SDI) today announced its operational highlights and financial results for the fiscal year ended December 31, 2009.
SEOUL, Korea, March 11, 2010-Medivir AB (Sweden) today announced a license agreement with Daewoong Pharmaceutical Co. Ltd., (South Korea) for its hepatitis B virus (HBV) polymerase inhibitor drug, lagociclovir valactate (MIV-210).
Milan, Italy, 11 March 2010 - Cosmo Pharmaceuticals S.p.A. informed BioXell that the offer according to the Offer Prospectus (as published by Cosmo Pharmaceuticals S.p.A. on 8 December 2009) has been executed as of today.
Hamburg, Germany - 11 March 2010: Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX) today announced that it has entered into a collaboration with Active Biotech AB (NASDAQ OMX: ACTI) to identify small molecule modulators of a priority biological target, selected by Active Biotech, involved in immune disorders and cancer.
Liège (Belgium) - March 11, 2010, 7:00 AM CET - OncoMethylome Sciences SA publishes its financial results for the period ended December 31, 2009.
Vienna, Austria, March 11, 2010 - Marinomed Biotechnologie GmbH, a company focused on the development of innovative therapies for respiratory diseases, announced today that it has been granted the European Patent No.2101792, entitled ‘Use of Carrageenan for treating Rhinovirus infections’ by the European Patent Office.
Copenhagen, Denmark; March 11, 2010 - Genmab A/S (OMX: GEN) announced today its President, R&D and Chief Scientific Officer, Prof. Jan van de Winkel, Ph.D. will attend the Kempen & Co. Life Sciences Conference on March 23 in Brussels, Belgium.
ESPOO, Finalnd, March 11, 2010-Member of the Board of Directors of Orion Corporation, Academician of Science, Professor, M.D., Ph.D. Leena Palotie has passed away after a serious illness.
BOTHELL, Wash.--(BUSINESS WIRE)--Mar 11, 2010 - Seattle Genetics, Inc. announced today that the U.S. Patent and Trademark Office has issued a patent related to its antibody-drug conjugate (ADC) technology. U.S. Patent No. 7,659,241 covers cleavable linkers and potent auristatin drug payloads used in certain of Seattle Genetics' ADC programs, most notably brentuximab vedotin (SGN-35), as well as many ADC programs in development by its collaborators.
Basel, Switzerland, March 11, 2010 - Basilea Pharmaceutica Ltd. announces that the Applicant Janssen-Cilag International NV, a Johnson & Johnson company, has submitted a request for re-examination of the negative opinion by the European Committee for Medicinal Products for Human Use on the Marketing Authorization Application for ceftobiprole for the treatment of complicated skin and soft tissue infections.
CHICAGO, March 11 /PRNewswire-FirstCall/ -- Advanced Life Sciences Holdings, Inc., a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, oncology and respiratory diseases, announced today that the U.S. Food and Drug Administration (FDA) has provided guidance on the clinical program required to assess the approvability of Restanza (cethromycin), a novel oral once-a-day antibiotic, in the treatment of outpatient community acquired bacterial pneumonia (CABP) as well as biodefense indications including anthrax, plague and tularemia.
|
